We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


  Gold Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Digital PCR Improves BCR-ABL1 Detection in Chronic Myeloid Leukemia

By LabMedica International staff writers
Posted on 22 Apr 2021
Print article
Image: The QX200 Droplet Digital Polymerase Chain Reaction (PCR) Systems provide ultrasensitive and absolute nucleic acid quantification. (Photo courtesy of Bio-Rad)
Image: The QX200 Droplet Digital Polymerase Chain Reaction (PCR) Systems provide ultrasensitive and absolute nucleic acid quantification. (Photo courtesy of Bio-Rad)
Specific targeting of the Bcr-Abl1 enzyme by tyrosine kinase inhibitors (TKI) revolutionized the management of chronic myeloid leukemia (CML) to the point that TKIs can offer near normal life expectancy for CML patients.

However, some CML patients do not achieve optimal response at defined treatment time points, and others even develop TKI resistance. Therefore, molecular monitoring is crucial for clinical management of CML. Digital PCR (dPCR) offers high reproducibility, precision and increased sensitivity for rare target detection.

Medical Scientists from various disciplines at the Masaryk University (Brno, Czech Republic) performed a retrospective analysis of 70 clinical samples from chronic phase CML patients and 15 samples from healthy volunteers used as BCR-ABL1 negative controls. Reverse-transcription (RT-qPCR) quantification of BCR-ABL1 in K562 cells was performed on an Applied Biosystems 7300 Real-Time PCR System (Waltham, MA, USA). The Xpert BCR-ABL Monitor test (Cepheid, Sunnyvale, CA, USA) was used for quantification of BCR-ABL1 in clinical CML samples. All dPCR measurements were performed on the on QX200 Droplet Digital PCR System (Bio-Rad, Hercules, CA, USA).

The investigators reported that despite overall correlation of ratios, they observed significant differences in copy numbers quantification between RT-qPCR and dPCR. In the samples containing high transcript levels (10%–0.1% BCR-ABL1IS), RT-qPCR detected significantly more BCR-ABL1 copies than dPCR (P < 0.0001). Conversely, in the sample with low transcript levels (0.0032% BCR-ABL1IS), RT-qPCR quantified significantly less BCR-ABL1 copies compared to dPCR. Moreover, in all sample categories dPCR detected significantly less ABL1 copies. A total of 44 CML patients, routinely monitored by GeneXpert, were tested by dPCR. The team observed significant differences in the ratios measured by dPCR and GeneXpert in the 36 patients with low transcript levels (≤0.1% BCR-ABL1IS), which also resulted in low correlation between the methods.

The authors concluded that their study demonstrated that droplet dPCR, tested with standard EAC assays, provided a detection limit of above three BCR-ABL1 copies/sample, which corresponded to sensitivity of conventional quantitative methods. Nevertheless, dPCR categorized more than 50% of the CML patients into different MR categories compared to quantitative GeneXpert. The study was published in the May, 2021 issue of the journal Practical Laboratory Medicine.

Related Links:
Masaryk University
Applied Biosystems

Gold Supplier
Desktop Urine Analyzer
Automated Molecular Diagnostic Analyzer
AutoMolec 1600
Automatic Biochemistry Analyzer
Falcon 260
PCR Workstations
AC600 Series

Print article
IIR Middle East



view channel
Image: QX200 AutoDG ddPCR System and QXDx BCR-ABL %IS Kit (Photo courtesy of Bio-Rad)

ddPCR Developed for BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia

Droplet digital polymerase chain reaction (ddPCR) is a novel polymerase chain reaction (PCR) technique reliant on massive sample partitioning to generate individual reaction chambers (droplets) in which... Read more


view channel

Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots

The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.